Neuropace Inc Stock Price, News & Analysis

NeuroPace (NPCE) reported strong Q4 2024 financial results with record quarterly revenue of $21.5 million, up 19% year-over-year. Full-year 2024 revenue increased 22% to $79.9 million.

The company completed a public offering of $74.8 million, using $49.5 million to repurchase KCK holdings and $20.2 million to strengthen its balance sheet. Gross margin reached 73.9% in 2024, while operating expenses were $80.8 million.

Key developments include:

• NAUTILUS pivotal study completion expected March 2025
• Project CARE showing increased implants and referrals
• New NEST program using real-world data from 27 pediatric centers
• Development of AI-enabled software tools and remote programming

For 2025, NeuroPace projects revenue between $92-96 million, representing 15-20% growth, with gross margin expected between 73-75%.

NeuroPace (Nasdaq: NPCE), a medical device company specializing in epilepsy treatment solutions, has announced its participation in the upcoming Leerink Partners 2025 Global Healthcare Conference. The company's management team is scheduled to present on Monday, March 10, 2025, at 4:20pm ET (1:20pm PT) in Miami, FL.

The presentation will be available through a live webcast, with a replay accessible for two weeks afterward through the Events section of NeuroPace's Investor website. Additionally, the management team will be conducting investor meetings throughout the conference.

NeuroPace (Nasdaq: NPCE), a medical device company specializing in epilepsy treatment solutions, has announced its participation in the upcoming Leerink Partners 2025 Global Healthcare Conference in Miami, FL.

The company's management team is scheduled to present on Monday, January 10, 2025, at 4:20pm ET (1:20pm PT). In addition to the presentation, the management will be conducting investor meetings throughout the conference.

Interested parties can access the presentation through a live webcast, with a replay available for two weeks following the event on the Events section of NeuroPace's Investor website at investors.neuropace.com.

NeuroPace (NPCE) has completed its previously announced repurchase of 5,270,845 shares of common stock from KCK , representing KCK's entire remaining stake in the company. The repurchase was funded using proceeds from NeuroPace's recent underwritten public offering.

The company has also terminated its current at-the-market (ATM) offering program. Following the public offering, NeuroPace reports a strengthened balance sheet that it expects will support planned operations until reaching cash flow breakeven.

CEO Joel Becker expressed satisfaction with the recent financing interest and welcomed new investors, while acknowledging KCK 's historical support. The company maintains that the remaining proceeds from the financing will enable execution of its long-range plan presented at last month's investor day in New York City.

NeuroPace (NPCE), a medical device company specializing in epilepsy treatment, has announced its upcoming financial results release for Q4 and full-year 2024. The results will be disclosed after market close on March 4, 2025. The company will host a conference call at 1:30 PM Pacific Time / 4:30 PM Eastern Time on the same day.

Investors can access the live webcast and participate in the call via telephone by dialing +1-877-407-3982 with Conference ID 13751530. The webcast recording will be available for at least 90 days on the company's investor relations website.

NeuroPace (NPCE) has completed its public offering of 7,475,000 shares of common stock at $10.00 per share, including 975,000 shares from the underwriters' option exercise. The offering generated gross proceeds of $74.8 million.

The company plans to use $49.5 million to repurchase 5,270,845 shares from KCK at $9.40 per share. The remaining proceeds will fund general corporate purposes, including clinical trials, R&D, administrative expenses, debt reduction, and working capital.

The offering was managed by J.P. Morgan, Cantor, Wells Fargo Securities, and Leerink Partners as joint book-running managers, with Lake Street Capital Markets as lead manager.

NeuroPace (NPCE) has announced the pricing of a public offering of 6.5 million shares of common stock at $10.00 per share, expecting to raise $65 million in gross proceeds. The offering, set to close on February 18, 2025, includes a 30-day option for underwriters to purchase up to 975,000 additional shares.

The company plans to use $49.5 million of the net proceeds to repurchase approximately 5.27 million shares from KCK at $9.40 per share. The remaining proceeds will fund general corporate purposes, including clinical trials, R&D expenses, administrative costs, debt reduction, and working capital.

The offering is managed by J.P. Morgan, Cantor, Wells Fargo Securities, and Leerink Partners as joint book-running managers, with Lake Street Capital Markets as lead manager.

NeuroPace (NPCE) has announced plans for a $65 million public offering of common stock, with an additional 30-day option for underwriters to purchase up to 15% more shares. A substantial portion of the proceeds will be used to repurchase all shares held by KCK , a significant stockholder, at the same price per share as the public offering.

The remaining proceeds will fund general corporate purposes, including clinical trials, R&D expenses, selling, general and administrative expenses, debt reduction, and working capital. The offering's joint book-running managers are J.P. Morgan, Cantor, Wells Fargo Securities, and Leerink Partners, with Lake Street Capital Markets as lead manager.

The offering will be made through a shelf registration statement previously declared effective by the SEC on November 22, 2022.

NeuroPace (NPCE), a medical device company specializing in epilepsy treatment, announced that data from their RNS System Post-approval Study will be presented at the American Academy of Neurology (AAN) 2025 Annual Meeting. The presentation, titled 'Multicenter Post-approval Study of the RNS System in Focal Epilepsy,' will be delivered by Dr. Dawn Eliashiv, Professor of Neurology and Co-Director of UCLA Seizure Disorders Center. The session is scheduled for Monday, April 7th, at 5:06 PM PT during the Epilepsy Clinical Outcomes and Prognostication session at the conference being held in San Diego from April 5th to 9th.